Primecap Management Co. CA Raises Position in Sanofi $SNY

Primecap Management Co. CA lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 3.2% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 1,135,528 shares of the company’s stock after purchasing an additional 34,890 shares during the period. Primecap Management Co. CA’s holdings in Sanofi were worth $54,857,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nuveen LLC acquired a new position in shares of Sanofi during the 1st quarter worth $177,831,000. Federated Hermes Inc. lifted its position in shares of Sanofi by 58.5% during the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock valued at $218,933,000 after acquiring an additional 1,456,269 shares during the period. OLD Mission Capital LLC acquired a new stake in shares of Sanofi in the 1st quarter worth approximately $48,938,000. Regal Partners Ltd increased its stake in Sanofi by 102.3% in the 2nd quarter. Regal Partners Ltd now owns 1,548,204 shares of the company’s stock valued at $74,794,000 after purchasing an additional 782,838 shares in the last quarter. Finally, Raymond James Financial Inc. boosted its position in Sanofi by 15.1% during the first quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock worth $179,914,000 after purchasing an additional 425,597 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on SNY shares. Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a report on Tuesday, November 11th. Finally, Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $62.67.

Sanofi Price Performance

SNY opened at $49.55 on Thursday. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The company’s 50 day simple moving average is $49.21 and its 200 day simple moving average is $49.35. The stock has a market capitalization of $121.67 billion, a PE ratio of 11.60, a P/E/G ratio of 1.38 and a beta of 0.49. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.94 and a current ratio of 1.06.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 24th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.10. The company had revenue of $14.53 billion for the quarter, compared to the consensus estimate of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. Sanofi’s revenue was down 7.5% on a year-over-year basis. During the same quarter last year, the firm posted $2.25 earnings per share. As a group, sell-side analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.